Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

IMPORTANCE: Immunomodulatory anticancer drugs, such as the anti–programmed death-1 drug pembrolizumab, have shown promising results in trials, and more patients will receive such treatments. Little is known about cutaneous adverse events (AEs) caused by these drugs and their possible correlation wit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Dermatol
Main Authors: Sanlorenzo, Martina, Vujic, Igor, Daud, Adil, Algazi, Alain, Gubens, Matthew, Luna, Sara Alcántara, Lin, Kevin, Quaglino, Pietro, Rappersberger, Klemens, Ortiz-Urda, Susana
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5061067/
https://ncbi.nlm.nih.gov/pubmed/26222619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2015.1916
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados